Literature DB >> 5075513

Specific radioactive labeling of terminal n-acetylgalactosamine of glycosphingolipids by the galactose oxidase-sodium borohydride method.

Y Suzuki, K Suzuki.   

Abstract

The galactose oxidase-sodium borohydride method was used to specifically label the terminal N-acetylgalactosamine of three glycosphingolipids, Gm2-ganglioside, asialo-Gm2-ganglioside, and globoside. All of the compounds showed a minimum of 95% radiopurity, and generally more than 90% of the total radioactivity was located in the terminal galactosamine moiety. Globoside and asialo-Gm2-ganglioside were labeled to high specific activities comparable with those of the sphingolipids with a terminal galactose moiety, labeled with the same procedure. These labeled compounds were well suited as substrates for the study of specific sphingolipid N-acetylgalactosaminidase. Gm2-ganglioside, however, was a poor substrate for galactose oxidase, and its specific activity was only a small percentage of the others. Furthermore, because of the low specific activity of the galactosamine moiety, it was necessary to pretreat Gm2-ganglioside with unlabeled sodium borohydride to reduce the nonspecific labeling of other portions of the molecule. The use of labeled sodium borohydride of a very high specific activity may yield specifically labeled Gm2-ganglioside suitable for metabolic studies. Thus, the method is useful for labeling not only terminal galactose but also terminal N-acetylgalactosamine of glycosphingolipids.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 5075513

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  30 in total

1.  Charged membrane surfaces impede the protein-mediated transfer of glycosphingolipids between phospholipid bilayers.

Authors:  P Mattjus; H M Pike; J G Molotkovsky; R E Brown
Journal:  Biochemistry       Date:  2000-02-08       Impact factor: 3.162

2.  Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease.

Authors:  P Leinekugel; S Michel; E Conzelmann; K Sandhoff
Journal:  Hum Genet       Date:  1992-03       Impact factor: 4.132

3.  Enzyme therapy in Fabry disease: differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase A isozymes.

Authors:  R J Desnick; K J Dean; G Grabowski; D F Bishop; C C Sweeley
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

4.  Functional incorporation of ganglioside into intact cells: induction of choleragen responsiveness.

Authors:  J Moss; P H Fishman; V C Manganiello; M Vaughan; R O Brady
Journal:  Proc Natl Acad Sci U S A       Date:  1976-04       Impact factor: 11.205

5.  Hexosaminidase assays.

Authors:  Michaela Wendeler; Konrad Sandhoff
Journal:  Glycoconj J       Date:  2009-11       Impact factor: 2.916

6.  A monoclonal antibody for terminal beta-galactose. Use in analysis of glycosphingolipids.

Authors:  A Kalisiak; E Oosterwijk; J G Minniti; L J Old; D A Scheinberg
Journal:  Glycoconj J       Date:  1991-02       Impact factor: 2.916

7.  Specific Identification of Glycoproteins Bearing the Tn Antigen in Human Cells.

Authors:  Jiangnan Zheng; Haopeng Xiao; Ronghu Wu
Journal:  Angew Chem Int Ed Engl       Date:  2017-05-17       Impact factor: 15.336

8.  Rat liver Golgi galactosyltransferases. Distinct enzymes for glycolipid and glycoprotein acceptor substrates.

Authors:  F Kaplan; P Hechtman
Journal:  Biochem J       Date:  1984-01-15       Impact factor: 3.857

9.  Behavior of gangliosides on dialysis.

Authors:  R Ghidoni; S Sonnino; G Tettamanti
Journal:  Lipids       Date:  1978-11       Impact factor: 1.880

10.  Stability of carbohydrate-modified vesicles in vivo: comparative effects of ceramide and cholesterol glycoconjugates.

Authors:  P S Wu; H M Wu; G W Tin; J R Schuh; W R Croasmun; J D Baldeschwieler; T Y Shen; M M Ponpipom
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.